Table 3.
Cox regression analysis for incidence of hepatocellular carcinoma.
| Characteristics | Univariable |
Multivariable |
||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p value∗ | Hazard ratio (95% CI) | p value∗ | |
| Antiviral agents | ||||
| TAF | 1 (ref) | — | 1 (ref) | — |
| TDF | 1.285 (1.148-1.439) | <0.001 | 1.335 (1.193-1.495) | <0.001 |
| ETV | 1.115 (0.993-1.252) | 0.066 | 1.162 (1.034-1.306) | 0.011 |
| Age (years) | 1.042 (1.037-1.046) | <0.001 | 1.041 (1.037-1.046) | <0.001 |
| Male | 2.239 (2.019-2.482) | <0.001 | 2.496 (2.247-2.773) | <0.001 |
| Duration of antiviral medication (days) | 1.000 (1.000-1.001) | <0.001 | 1.000 (1.000-1.001) | <0.001 |
| Presence of liver cirrhosis | 4.373 (3.997-4.785) | <0.001 | 3.102 (2.819-3.413) | <0.001 |
| Decompensated cirrhosis | 2.865 (2.534-3.239) | <0.001 | 1.627 (1.430-1.850) | <0.001 |
| Charlson Comorbidity Index score | 0.975 (0.944-1.006) | 0.110 | — | — |
∗
p values were evaluated using Cox regression analysis. ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.